Navigation Links
Exiqon Announces Positive Clinical Data From EORTC Clinical Trial Showing Oncotech EDR Assay Predicts Resistance to Platinum-Based Therapy in Ovarian Cancer
Date:10/27/2008

nue to collaborate with key research organizations to support the clinical use of the Oncotech EDR Assay."

Lars Kongsbak, CEO says: "This study is an important part of our effort to create an expanding portfolio of clinical studies supporting our diagnostic tests. Clinical evidence of this kind accomplishes three objectives: to demonstrate to the pharmaceutical research and clinical oncology communities that the Oncotech EDR Assay platform is a validated testing instrument leading to increased adoption by the oncology community; to strengthen clinical support of the Oncotech EDR Assay technology required by healthcare insurers for optimal reimbursement; and to validate the Oncotech EDR Assay results further substantiating the technology as a key platform that can be leveraged as a reference in the identification of molecular signatures of chemoresistance. The latter is offered to our customers through Exiqon Pharma Services."

About Exiqon

Exiqon is a biotech company with activities in three business areas where the company's technologies provide a competitive advantage: sale of diagnostic tests (Exiqon Diagnostics), sale of innovative research products for miRNA research (Exiqon Life Sciences), and in contract research together with pharmaceutical companies (Exiqon Pharma Services). Exiqon is dedicated to personalizing the treatment selection for cancer patients. The aim is to optimize the use of existing medicine and avoid unnecessary and non-effective treatment. By using molecular diagnostic tests that analyse the genetic profile of each patient's tumor, treatment selection can be optimized for individuals. Exiqon is uniquely positioned to develop such new diagnostic tests. Exiqon already markets diagnostic tests that based on fresh tumor tissue enable doctors to test whether their patients are resistant to one or more of the chemotherapies offered to treat these patients and help them select an efficacious treatment. Exiqons new molecular dia
'/>"/>

SOURCE Exiqon A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Exiqon: Major Shareholder Announcement
2. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
3. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
4. Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
5. Report Regarding the Managements and Closely Related Parties Transactions With Securities in Exiqon A/S
6. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
7. Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc.
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Product and ... very low abundance and are often “lost in ... time-consuming. , Join presenters Dr. Rowel Tobias, Senior ... John Anders, Head of Quality at Nanotherapeutics, Inc., ... that can speed detection and quantitation while achieving ...
(Date:7/10/2014)... Robert Harman, DVM, Founder and CEO of Vet-Stem, ... announce the relaunch of his highly informative blog, now named ... “ What are Stem Cells ?” Dr. Harman’s purpose ... in the basics of stem cell therapy so that pet ... of treatment when considering regenerative medicine. , A veterinarian by ...
(Date:7/10/2014)... 10, 2014 On July 9 ... , presented Russia,s first national ... The Company is developing a unique project called ... develops a number of innovative drugs based on monoclonal ... ceremony took place at the International Exhibition "Innoprom 2014" ...
(Date:7/10/2014)... D.C., April 15, 2014 -- According to the ... to nuclear security comes from terrorists acquiring sufficient ... to construct a crude nuclear explosive device. The ... nuclear trafficking have involved gram-level quantities, which can ... , According to a new study appearing this ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Sensitive detection method may help impede illicit nuclear trafficking 2
... 7, 2011 Regado Biosciences, Inc., a privately ... with active control agents, announced the presentation of ... Company,s Phase 2b RADAR trial of REG1, Regado,s ... at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium meeting ...
... Inc. (NYSE AMEX: IBIO ) today announced that ... its 2011 Annual Stockholders Meeting to be held December 8, 2011 ... at 11:00 AM ET. Although only stockholders of ... will be entitled to vote at the meeting, anyone with proof ...
... The shortlist of contenders for the highest ... narrowed tonight as the winners of the Siemens ... Finals were announced.  Cancer stem cell research earned ... Angela Zhang of Cupertino, California.  Research on molecular ...
Cached Biology Technology:Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011 2Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011 3Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011 4iBio Sets Record Date and Location for December 8 Annual Meeting of Stockholders 2Biochemistry and Bioengineering Research Brings California Students Closer to Nation's Highest Science Honor for High School Students 2Biochemistry and Bioengineering Research Brings California Students Closer to Nation's Highest Science Honor for High School Students 3Biochemistry and Bioengineering Research Brings California Students Closer to Nation's Highest Science Honor for High School Students 4Biochemistry and Bioengineering Research Brings California Students Closer to Nation's Highest Science Honor for High School Students 5
(Date:7/11/2014)... The increased risk of kidney injury related to ... reflects the mass of HES molecules, according to a ... of the International Anesthesia Research Society (IARS). , The ... of HES on cultured human renal proximal tubule cells ... and colleagues of University Hospital Wrzburg, Austria. Other ...
(Date:7/11/2014)... 1 can inhibit voltage-gated calcium channel, decrease ... However, some scholars demonstrated that cannabinoid receptor ... and increase neurotransmitter release. Dr. Yi Zhang ... Tongji Medical College, Huazhong University of Science ... and calcium imaging in cultured trigeminal ganglion ...
(Date:7/10/2014)... In Santa Fe, Albuquerque, and other major cities in ... watered with treated municipal wastewater rather than precious potable ... more than 40% of all golf courses receive treated ... courses. , Additionally, golf courses and homeowners alike ... nutrient in fertilizer is nitrate. A New Mexico State ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2'Tailored' water -- the latest in lawn care 2
... -- Findings from a first-of-its-kind study by Indiana University ... or fantasies -- can lead to female orgasm. ... phenomenon, sometimes called "coregasm" because of its association with ... media for years, said Debby Herbenick, co-director of the ...
... Georgetown University Medical Center have revealed how a mutation in ... to effectively pass along appetite suppressing signals from the body ... obesity caused by a voracious appetite. , Their study, published ... might be a way to stimulate expression of that gene ...
... a proton the bare nucleus of a hydrogen atom ... a molecule, the result is a hydrogen bond, in which ... electrons. Conventional wisdom has it that proton transfers can only ... networks that can connect and reconnect to alter molecular properties. ...
Cached Biology News:Study: Exercise can lead to female orgasm, sexual pleasure 2Study: Exercise can lead to female orgasm, sexual pleasure 3Researchers reveal how a single gene mutation leads to uncontrolled obesity 2A surprising new kind of proton transfer 2A surprising new kind of proton transfer 3A surprising new kind of proton transfer 4
Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
... Sight DS-L2 imaging controller is a successor ... and allows users to comfortably observe, record ... controller features an 8.4 inch LCD (XGA) ... of Nikon cameras including the DS-Fi1 , ...
... is a premium quality recombinant form of ... is suitable for a wide range of ... and reproducible performance, each preparation is extensively ... assays. NovaTaq DNA Polymerase possesses an integral ...
Mouse polyclonal antibody raised against a partial recombinant TSEN2. NCBI Entrez Gene ID = 80746...
Biology Products: